# Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

> **NCT06387121** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 53 (estimated)

## Conditions studied

- Precursor Cell Lymphoblastic Leukemia-Lymphoma

## Interventions

- **DRUG:** Vincristine
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone
- **DRUG:** Venetoclax
- **DRUG:** Inotuzumab ozogamicin
- **DRUG:** Blinatumomab
- **DRUG:** 6-mercaptopurine
- **DRUG:** Methotrexate
- **DRUG:** Cytarabine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT06387121
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-02
- **Primary completion:** 2026-12-01
- **Final completion:** 2028-12-31
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06387121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06387121, "Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06387121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*